Here's the actually study report
Neonatal Abstinence Syndrome After In Utero Exposure to Selective
Serotonin Reuptake Inhibitors in Term Infants
Rachel Levinson-Castiel, MD; Paul Merlob, MD; Nehama Linder, MD; Lea
Sirota, MD; Gil Klinger, MD
Arch Pediatr Adolesc Med. 2006;160:173-176.
Objective To compare the prevalence and clinical characteristics of
neonatal abstinence syndrome in neonates exposed and not exposed to
selective serotonin reuptake inhibitors (SSRIs) in utero.
Design Cohort study.
Setting Tertiary care center.
Patients One hundred twenty term infants, of whom 60 had prolonged
in utero exposure to SSRIs, including paroxetine hydrochloride,
fluoxetine, citalopram hydrobromide, sertraline hydrochloride, and
Main Outcome Measures Neonatal abstinence syndrome was assessed with
the Finnegan score as follows: score of 8 or above, severe; score of
4 to 7, mild; and score of 0 to 3, normal. All infants were followed
up with a standardized protocol that included repeated Finnegan
score assessments and cardiorespiratory monitoring until
normalization of the Finnegan score.
Results Of the 60 neonates exposed to SSRIs in utero, 8 showed
severe and 10 showed mild symptoms of a neonatal abstinence
syndrome. All nonexposed neonates had a normal Finnegan score. In
neonates who developed severe symptoms, the maximum mean daily
Finnegan scores were recorded within 2 days after birth, although
maximum individual scores were recorded as long as 4 days after
Conclusions Neonatal abstinence syndrome occurs in 30% of neonates
exposed to SSRIs in utero. These neonates should be monitored for at
least 48 hours after birth. The long-term effects of prolonged
exposure to SSRIs, particularly in neonates who develop severe
symptoms, have yet to be determined.
Author Affiliations: Neonatal Intensive Care Unit, Schneider
Children's Medical Center of Israel, Petah Tiqwa (Drs Levinson-
Castiel, Merlob, Linder, Sirota, and Klinger); Department of
Neonatology, Rabin Medical Center, Petah Tiqwa (Drs Merlob, Linder,
Sirota, and Klinger); and Sackler School of Medicine, Tel Aviv
University, (Drs Merlob, Linder, Sirota, and Klinger), Tel Aviv,